{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T13:37:40Z","timestamp":1790861860302,"version":"4.1.0"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100001819","name":"International Rett Syndrome Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.neuropharm.2012.06.024","type":"journal-article","created":{"date-parts":[[2012,6,27]],"date-time":"2012-06-27T11:33:08Z","timestamp":1340796788000},"page":"136-142","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"special_numbering":"C","title":["Gene therapy and neurodevelopmental disorders"],"prefix":"10.1016","volume":"68","author":[{"given":"Steven James","family":"Gray","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2012.06.024_bib1","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1093\/hmg\/ddi402","article-title":"A\u00a0segment of the Mecp2 promoter is sufficient to drive expression in neurons","volume":"14","author":"Adachi","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2012.06.024_bib2","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/13810","article-title":"Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2","volume":"23","author":"Amir","year":"1999","journal-title":"Nat. Genet."},{"key":"10.1016\/j.neuropharm.2012.06.024_bib3","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ymthe.2004.05.024","article-title":"Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system","volume":"10","author":"Burger","year":"2004","journal-title":"Mol. Ther."},{"key":"10.1016\/j.neuropharm.2012.06.024_bib4","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1126\/science.1171242","article-title":"Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy","volume":"326","author":"Cartier","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2012.06.024_bib5","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ymthe.2005.11.015","article-title":"Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain","volume":"13","author":"Cearley","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.neuropharm.2012.06.024_bib6","doi-asserted-by":"crossref","first-page":"9928","DOI":"10.1523\/JNEUROSCI.2185-07.2007","article-title":"A\u00a0single injection of an adeno-associated virus vector into nuclei with divergent connections results in widespread vector distribution in the brain and global correction of a neurogenetic disease","volume":"27","author":"Cearley","year":"2007","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2012.06.024_bib7","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1365-2990.1979.tb00629.x","article-title":"A\u00a0quantitative study of cell proliferation in ependyma and choroid plexus in the postnatal rat brain","volume":"5","author":"Chauhan","year":"1979","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.neuropharm.2012.06.024_bib8","doi-asserted-by":"crossref","unstructured":"Chen, Y.H., Chang, M., Davidson, B.L., 2009. Molecular signatures of disease brain endothelia provide new sites for CNS-directed enzyme therapy. Nat. Med. 15, 1215\u20131218.","DOI":"10.1038\/nm.2025"},{"key":"10.1016\/j.neuropharm.2012.06.024_bib9","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1093\/hmg\/ddh282","article-title":"Mild overexpression of MeCP2 causes a progressive neurological disorder in mice","volume":"13","author":"Collins","year":"2004","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2012.06.024_bib10","doi-asserted-by":"crossref","first-page":"e27221","DOI":"10.1371\/journal.pone.0027221","article-title":"Adeno-associated virus-mediated rescue of the cognitive defects in a mouse model for Angelman syndrome","volume":"6","author":"Daily","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2012.06.024_bib11","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1073\/pnas.97.7.3428","article-title":"Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system","volume":"97","author":"Davidson","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.neuropharm.2012.06.024_bib12","article-title":"Long-term efficacy following readministration of an AAV vector in dogs with glycogen storage disease type Ia","author":"Demaster","year":"2011","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.neuropharm.2012.06.024_bib13","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nature10907","article-title":"Wild-type microglia arrest pathology in a mouse model of Rett syndrome","volume":"484","author":"Derecki","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2012.06.024_bib14","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/mt.2008.60","article-title":"Delivery of AAV-IGF-1 to the CNS extends survival in ALS mice through modification of aberrant glial cell activity","volume":"16","author":"Dodge","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.neuropharm.2012.06.024_bib15","doi-asserted-by":"crossref","DOI":"10.1038\/mt.2009.71","article-title":"Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons","author":"Duque","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.neuropharm.2012.06.024_bib16","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1056\/NEJMoa042604","article-title":"Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease","volume":"352","author":"Escolar","year":"2005","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2012.06.024_bib17","article-title":"Robust spinal motor neuron transduction following intrathecal delivery of AAV9 in pigs","author":"Federici","year":"2011","journal-title":"Gene Ther."},{"key":"10.1016\/j.neuropharm.2012.06.024_bib18","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nbt.1515","article-title":"Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes","volume":"27","author":"Foust","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.neuropharm.2012.06.024_bib19","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nbt.1610","article-title":"Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN","volume":"28","author":"Foust","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.neuropharm.2012.06.024_bib20","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/mt.2011.34","article-title":"Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood-brain barrier gene delivery","volume":"19","author":"Fu","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.neuropharm.2012.06.024_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/BJ20110648","article-title":"MeCP2 and Rett syndrome: reversibility and potential avenues for therapy","volume":"439","author":"Gadalla","year":"2011","journal-title":"Biochem. J."},{"key":"10.1016\/j.neuropharm.2012.06.024_bib22","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/gt.2010.141","article-title":"microRNA122-regulated transgene expression increases specificity of cardiac gene transfer upon intravenous delivery of AAV9 vectors","volume":"18","author":"Geisler","year":"2011","journal-title":"Gene Ther."},{"key":"10.1016\/j.neuropharm.2012.06.024_bib23","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1073\/pnas.0610593104","article-title":"Partial rescue of MeCP2 deficiency by postnatal activation of MeCP2","volume":"104","author":"Giacometti","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.neuropharm.2012.06.024_bib24","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1743-422X-2-43","article-title":"Adeno-associated virus: from defective virus to effective vector","volume":"2","author":"Goncalves","year":"2005","journal-title":"Virol. J."},{"key":"10.1016\/j.neuropharm.2012.06.024_bib25","doi-asserted-by":"crossref","unstructured":"Gray, S.J., Foti, S.B., Schwartz, J.W., Bachaboina, L., Taylor-Blake, B., Coleman, J., Ehlers, M.D., Zylka, M.J., McCown, T.J., Samulski, R.J., 2011a. Optimizing promoters for rAAV-mediated gene expression in the peripheral and central nervous system using self-complementary vectors. Hum. Gene Ther.","DOI":"10.1089\/hum.2010.245"},{"key":"10.1016\/j.neuropharm.2012.06.024_bib26","doi-asserted-by":"crossref","DOI":"10.1089\/hum.2010.245","article-title":"Optimizing promoters for rAAV-mediated gene expression in the peripheral and central nervous system using self-complementary vectors","author":"Gray","year":"2011","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.neuropharm.2012.06.024_bib27","doi-asserted-by":"crossref","DOI":"10.1089\/hum.2010.245","article-title":"Optimizing promoters for recombinant adeno-associated virus-mediated gene expression in the peripheral and central nervous system using self-complementary vectors","author":"Gray","year":"2011","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.neuropharm.2012.06.024_bib28","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1038\/mt.2011.72","article-title":"Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates","volume":"19","author":"Gray","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.neuropharm.2012.06.024_bib30","doi-asserted-by":"crossref","first-page":"517","DOI":"10.4155\/tde.10.50","article-title":"Viral vectors and delivery strategies for CNS gene therapy","volume":"1","author":"Gray","year":"2010","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.neuropharm.2012.06.024_bib31","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1126\/science.1138389","article-title":"Reversal of neurological defects in a mouse model of Rett syndrome","volume":"315","author":"Guy","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2012.06.024_bib32","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/ana.410140412","article-title":"A\u00a0progressive syndrome of autism, dementia, ataxia, and loss of purposeful hand use in girls: Rett's syndrome: report of 35 cases","volume":"14","author":"Hagberg","year":"1983","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2012.06.024_bib33","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jviromet.2006.03.031","article-title":"Improved high-capacity adenoviral vectors for high-level neuron-restricted gene transfer to the CNS","volume":"136","author":"Hermening","year":"2006","journal-title":"J.\u00a0Virol. Methods"},{"key":"10.1016\/j.neuropharm.2012.06.024_bib34","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/sj.mt.6300367","article-title":"Efficient retrograde neuronal transduction utilizing self-complementary AAV1","volume":"16","author":"Hollis","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.neuropharm.2012.06.024_bib35","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/gt.2009.52","article-title":"Long-term AAV vector gene and protein expression in mouse brain from a small pan-cellular promoter is similar to neural cell promoters","volume":"16","author":"Husain","year":"2009","journal-title":"Gene Ther."},{"key":"10.1016\/j.neuropharm.2012.06.024_bib36","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1089\/104303402760128612","article-title":"Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain","volume":"13","author":"Janson","year":"2002","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.neuropharm.2012.06.024_bib37","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S0896-6273(00)80596-6","article-title":"Mutation of the Angelman ubiquitin ligase in mice causes increased cytoplasmic p53 and deficits of contextual learning and long-term potentiation","volume":"21","author":"Jiang","year":"1998","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2012.06.024_bib38","doi-asserted-by":"crossref","first-page":"e22166","DOI":"10.1371\/journal.pone.0022166","article-title":"MicroRNA-restricted transgene expression in the retina","volume":"6","author":"Karali","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2012.06.024_bib39","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/mt.2008.15","article-title":"AAV vector-mediated reversal of hypoglycemia in canine and murine glycogen storage disease type Ia","volume":"16","author":"Koeberl","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.neuropharm.2012.06.024_bib40","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nprot.2006.93","article-title":"Construction of diverse adeno-associated viral libraries for directed evolution of enhanced gene delivery vehicles","volume":"1","author":"Koerber","year":"2006","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.neuropharm.2012.06.024_bib41","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1006\/mcne.2000.0929","article-title":"Neuron-specific expression of therapeutic proteins: evaluation of different cellular promoters in recombinant adenoviral vectors","volume":"17","author":"Kugler","year":"2001","journal-title":"Mol. Cell Neurosci."},{"key":"10.1016\/j.neuropharm.2012.06.024_bib42","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/glia.20622","article-title":"GFAP promoter elements required for region-specific and astrocyte-specific expression","volume":"56","author":"Lee","year":"2008","journal-title":"Glia"},{"key":"10.1016\/j.neuropharm.2012.06.024_bib43","article-title":"Viral vectors for gene delivery to the central nervous system","author":"Lentz","year":"2011","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2012.06.024_bib44","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/nature10214","article-title":"A\u00a0role for glia in the progression of Rett's syndrome","volume":"475","author":"Lioy","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2012.06.024_bib45","doi-asserted-by":"crossref","first-page":"9321","DOI":"10.1523\/JNEUROSCI.2936-05.2005","article-title":"Functional correction of CNS phenotypes in a lysosomal storage disease model using adeno-associated virus type 4 vectors","volume":"25","author":"Liu","year":"2005","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2012.06.024_bib46","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1038\/sj.gt.3302554","article-title":"Adeno-associated virus type 4 (AAV4) targets ependyma and astrocytes in the subventricular zone and RMS","volume":"12","author":"Liu","year":"2005","journal-title":"Gene Ther."},{"key":"10.1016\/j.neuropharm.2012.06.024_bib47","doi-asserted-by":"crossref","first-page":"6033","DOI":"10.1073\/pnas.0401626101","article-title":"Expression of MeCP2 in postmitotic neurons rescues Rett syndrome in mice","volume":"101","author":"Luikenhuis","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.neuropharm.2012.06.024_bib48","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.tins.2011.04.001","article-title":"Angelman syndrome: insights into genomic imprinting and neurodevelopmental phenotypes","volume":"34","author":"Mabb","year":"2011","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2012.06.024_bib49","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/nbt1182","article-title":"Directed evolution of adeno-associated virus yields enhanced gene delivery vectors","volume":"24","author":"Maheshri","year":"2006","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.neuropharm.2012.06.024_bib50","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1038\/sj.gt.3302134","article-title":"Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in\u00a0vivo","volume":"10","author":"McCarty","year":"2003","journal-title":"Gene Ther."},{"key":"10.1016\/j.neuropharm.2012.06.024_bib51","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/sj.gt.3301514","article-title":"Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis","volume":"8","author":"McCarty","year":"2001","journal-title":"Gene Ther."},{"key":"10.1016\/j.neuropharm.2012.06.024_bib52","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/jgm.885","article-title":"Immune responses to AAV in a phase I study for Canavan disease","volume":"8","author":"McPhee","year":"2006","journal-title":"J.\u00a0Gene Med."},{"key":"10.1016\/j.neuropharm.2012.06.024_bib53","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1182\/blood-2008-10-181479","article-title":"Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy","volume":"113","author":"Niemeyer","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.neuropharm.2012.06.024_bib54","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/sj.gt.3300358","article-title":"Efficient transduction of green fluorescent protein in spinal cord neurons using adeno-associated virus vectors containing cell type-specific promoters","volume":"4","author":"Peel","year":"1997","journal-title":"Gene Ther."},{"key":"10.1016\/j.neuropharm.2012.06.024_bib55","doi-asserted-by":"crossref","unstructured":"Pulicherla, N., Shen, S., Yadav, S., Debbink, K., Govindasamy, L., Agbandje-McKenna, M., Asokan, A., 2011. Engineering liver-detargeted AAV9 vectors for cardiac and musculoskeletal gene transfer. Mol. Ther.","DOI":"10.1038\/mt.2011.22"},{"key":"10.1016\/j.neuropharm.2012.06.024_bib56","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/gt.2010.157","article-title":"Liver-specific microRNA-122 target sequences incorporated in AAV vectors efficiently inhibits transgene expression in the liver","volume":"18","author":"Qiao","year":"2011","journal-title":"Gene Ther."},{"key":"10.1016\/j.neuropharm.2012.06.024_bib57","doi-asserted-by":"crossref","first-page":"e10611","DOI":"10.1371\/journal.pone.0010611","article-title":"Systematic comparison of constitutive promoters and the doxycycline-inducible promoter","volume":"5","author":"Qin","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2012.06.024_bib58","doi-asserted-by":"crossref","first-page":"e6810","DOI":"10.1371\/journal.pone.0006810","article-title":"MECP2 isoform-specific vectors with regulated expression for Rett syndrome gene therapy","volume":"4","author":"Rastegar","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2012.06.024_bib59","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1182\/blood-2004-06-2501","article-title":"Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer","volume":"105","author":"Rivera","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.neuropharm.2012.06.024_bib60","article-title":"AAV9 transduction in the central nervous system of non-human primates","author":"Samaranch","year":"2011","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.neuropharm.2012.06.024_bib61","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.ymthe.2006.01.006","article-title":"Gene therapy for lysosomal storage diseases","volume":"13","author":"Sands","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.neuropharm.2012.06.024_bib62","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1651-2227.2008.00660.x","article-title":"CNS-directed gene therapy for lysosomal storage diseases","volume":"97","author":"Sands","year":"2008","journal-title":"Acta Paediatr. Suppl."},{"key":"10.1016\/j.neuropharm.2012.06.024_bib63","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1161\/01.CIR.0000138747.82487.4B","article-title":"Gene therapy ameliorates cardiovascular disease in dogs with mucopolysaccharidosis VII","volume":"110","author":"Sleeper","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.neuropharm.2012.06.024_bib64","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1126\/scitranslmed.3002627","article-title":"Increased gene dosage of Ube3a results in autism traits and decreased glutamate synaptic transmission in mice","volume":"3","author":"Smith","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.neuropharm.2012.06.024_bib65","doi-asserted-by":"crossref","DOI":"10.1089\/hum.2011.008","article-title":"Comparison of adeno-associated viral vector serotypes for spinal cord and motor neuron gene delivery","author":"Snyder","year":"2011","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.neuropharm.2012.06.024_bib66","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/mt.2008.283","article-title":"Detection of intact rAAV particles up to 6 years after successful gene transfer in the retina of dogs and primates","volume":"17","author":"Stieger","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.neuropharm.2012.06.024_bib67","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1073\/pnas.0708003105","article-title":"Sensory neuron targeting by self-complementary AAV8 via lumbar puncture for chronic pain","volume":"105","author":"Storek","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.neuropharm.2012.06.024_bib68","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/sj.mt.6300325","article-title":"Biochemical, pathological, and skeletal improvement of mucopolysaccharidosis VI after gene transfer to liver but not to muscle","volume":"16","author":"Tessitore","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.neuropharm.2012.06.024_bib69","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1744-8069-5-52","article-title":"Recombinant adeno-associated virus serotype 6 (rAAV2\/6)-mediated gene transfer to nociceptive neurons through different routes of delivery","volume":"5","author":"Towne","year":"2009","journal-title":"Mol. Pain"},{"key":"10.1016\/j.neuropharm.2012.06.024_bib70","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/sj.mt.6300201","article-title":"Correction of clinical manifestations of canine mucopolysaccharidosis I with neonatal retroviral vector gene therapy","volume":"15","author":"Traas","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.neuropharm.2012.06.024_bib71","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/nn1845","article-title":"Rescue of neurological deficits in a mouse model for Angelman syndrome by reduction of alphaCaMKII inhibitory phosphorylation","volume":"10","author":"van Woerden","year":"2007","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2012.06.024_bib72","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/ana.20392","article-title":"Effective gene therapy for an inherited CNS disease in a large animal model","volume":"57","author":"Vite","year":"2005","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2012.06.024_bib73","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1089\/hum.2008.022","article-title":"Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA","volume":"19","author":"Worgall","year":"2008","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.neuropharm.2012.06.024_bib74","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.ymthe.2006.05.009","article-title":"Adeno-associated virus serotypes: vector toolkit for human gene therapy","volume":"14","author":"Wu","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.neuropharm.2012.06.024_bib75","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/sj.mt.6300355","article-title":"Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose","volume":"16","author":"Wu","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.neuropharm.2012.06.024_bib76","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.virol.2005.06.051","article-title":"A\u00a0combination of mutations enhances the neurotropism of AAV-2","volume":"341","author":"Xu","year":"2005","journal-title":"Virology"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390812002821?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390812002821?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T23:54:01Z","timestamp":1762214041000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390812002821"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":75,"alternative-id":["S0028390812002821"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2012.06.024","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gene therapy and neurodevelopmental disorders","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2012.06.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}